Tamoxifen 10 mg
- Pickup from New Mail
- New Mail Courier
- Pickup from the store
- Other transport services
- Cash upon receipt
- Bank transfer
- Privat 24
- WebMoney
- Tamoxifen 10 mg
- Brand: Magnus Pharmaceuticals
- Content: 100 tablets | 10 mg per tablet
- Manufactured in: Europe
Product Overview
Tamoxifen 10 mg delivers a high-purity selective estrogen receptor modulator (SERM) used extensively in both endocrine and androgen-focused research. By binding to ER-/ receptors and blocking estrogen-mediated feedback on the hypothalamic–pituitary–gonadal (HPG) axis, tamoxifen promotes a cascade increase in LH, FSH, and endogenous testosterone in male models.
In female models, it remains the gold-standard anti-estrogen for ER-positive tumor protocols. Its high oral bioavailability (~100%) and long half-life (4–11 days for parent, up to 70 hours for active metabolite endoxifen) support once-daily use in long-range studies, including PCT, fertility, gynecomastia reversal, and hormone-modulation assays.
Key Research Highlights
- HPG-axis stimulation: 10–20 mg/day for 3 months doubled serum testosterone in hypogonadal males [PMC]
- Gynecomastia control: Clinical data show significant breast tissue regression in AAS-using males on 10–20 mg/day
- Anti-estrogen benchmark: First-line SERM for ER+ breast cancer research and comparative estrogen-blocking trials [NCBI]
- Pharmacokinetics: ~100% oral bioavailability; 4–11 day half-life (parent), 50–70 hours (endoxifen metabolite) [Wikipedia]
- Storage & stability: Film-coated tablets stable 25 °C with 36-month shelf-life — ideal for long-term protocols [PubChem, PubMed]
Suggested Laboratory Applications
HPG-axis and testosterone recovery models
Gynecomastia reversal and estrogenic side-effect prevention
SERM benchmarking in ER-positive breast-cancer assays
Post-cycle therapy research for anabolic models
Hormone-modulation pharmacokinetics
Technical Specifications
| Field | Data |
|---|---|
| Chemical Name | Tamoxifen (base); supplied as Tamoxifen Citrate |
| Chemical Formula | C<sub>26</sub>H<sub>29</sub>NO (base) |
| Synonyms | Nolvadex; TMX; 4-(1-dimethylaminoethoxy)-diphenyl-1-ethenyl-phenol |
| Molecular Weight | 371.5 g/mol (base); 563.6 g/mol (citrate) |
| CAS Number | 10540-29-1 (base); 54965-24-1 (citrate) |
| Half-life | Parent: 4–11 days · Endoxifen: 50–70 hours |
Detection Window
Long-acting — detectable for several weeks
Documented Benefits
LH/FSH, testosterone, gynecomastia, SERM gold standard
Main Risks
Hot-flushes, bone density, cataract risk, thrombo-embolism, lipid shifts
Total Active Compound
1,000 mg tamoxifen base per carton (10 mg 100 tablets)
Shelf-life
36 months (manufacturer specification)
PubChem-Supported Research Insights
Blocks estrogen feedback to HPG axis endogenous testosterone
Used clinically in both male infertility and female ER+ oncology
Demonstrated ability to reverse steroid-induced gynecomastia
Maintains receptor suppression up to 6 weeks post-use
Oral form preferred over injectable SERMs for logistical ease
Documented Research Side Effects
Hot-flushes, fatigue, and temporary visual disturbances
Lipid profile changes ( LDL / HDL) with long-term use
Thrombo-embolic events in susceptible models
Cataract formation risk at extended exposure
Reduced bone-mineral density (BMD) with prolonged protocols
Handling & Compliance
For Research Use Only — Not for human or veterinary useStore at 15–25°C, protect from light and moisturePurchase confirms qualified researcher statusListed on WADA Prohibited List S4 (Hormone Modulators) — any exposure may trigger positive test
-
Package:100 tablets | 10 mg per tablet
-
CAS Number:10540-29-1 (base); 54965-24-1 (citrate)
-
Molecular formula:C<sub>26</sub>H<sub>29</sub>NO (base)
-
Country of manufacture:Europe
-
Half-life:Parent: 4–11 days · Endoxifen: 50–70 hours